Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 234.9 Billion KRW | 7.57% |
| 2022 | 218.38 Billion KRW | 11.38% |
| 2021 | 196.06 Billion KRW | -5.95% |
| 2020 | 208.46 Billion KRW | -5.47% |
| 2019 | 220.51 Billion KRW | 18.3% |
| 2018 | 186.4 Billion KRW | -4.41% |
| 2017 | 195 Billion KRW | 0.97% |
| 2016 | 193.13 Billion KRW | 13.47% |
| 2015 | 170.2 Billion KRW | 1.57% |
| 2014 | 167.56 Billion KRW | 6.99% |
| 2013 | 156.62 Billion KRW | 13.75% |
| 2012 | 137.68 Billion KRW | 22.82% |
| 2011 | 112.1 Billion KRW | -3.62% |
| 2010 | 116.31 Billion KRW | 12.52% |
| 2009 | 103.37 Billion KRW | -6.75% |
| 2008 | 110.86 Billion KRW | 1.1% |
| 2007 | 109.65 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 64.94 Billion KRW | 0.99% |
| 2024 Q2 | 62.2 Billion KRW | -4.23% |
| 2024 Q3 | 62.04 Billion KRW | -0.26% |
| 2023 Q4 | 64.31 Billion KRW | 8.32% |
| 2023 Q1 | 54.18 Billion KRW | -9.03% |
| 2023 Q2 | 57.03 Billion KRW | 5.25% |
| 2023 FY | 234.9 Billion KRW | 7.57% |
| 2023 Q3 | 59.36 Billion KRW | 4.1% |
| 2022 Q3 | 54.32 Billion KRW | 4.17% |
| 2022 FY | 218.38 Billion KRW | 11.38% |
| 2022 Q1 | 52.33 Billion KRW | -2.95% |
| 2022 Q2 | 52.15 Billion KRW | -0.34% |
| 2022 Q4 | 59.56 Billion KRW | 9.65% |
| 2021 Q3 | 49.45 Billion KRW | 0.85% |
| 2021 Q4 | 53.92 Billion KRW | 9.03% |
| 2021 FY | 196.06 Billion KRW | -5.95% |
| 2021 Q1 | 43.64 Billion KRW | -13.94% |
| 2021 Q2 | 49.04 Billion KRW | 12.36% |
| 2020 Q3 | 49.97 Billion KRW | -1.66% |
| 2020 Q4 | 50.71 Billion KRW | 1.48% |
| 2020 FY | 208.46 Billion KRW | -5.47% |
| 2020 Q1 | 56.95 Billion KRW | 6.63% |
| 2020 Q2 | 50.81 Billion KRW | -10.77% |
| 2019 Q3 | 55.1 Billion KRW | -6.67% |
| 2019 FY | 220.51 Billion KRW | 18.3% |
| 2019 Q1 | 52.94 Billion KRW | -7.44% |
| 2019 Q2 | 59.04 Billion KRW | 11.53% |
| 2019 Q4 | 53.41 Billion KRW | -3.08% |
| 2018 Q2 | 38.99 Billion KRW | -18.8% |
| 2018 Q1 | 48.02 Billion KRW | -4.51% |
| 2018 FY | 186.4 Billion KRW | -4.41% |
| 2018 Q4 | 57.2 Billion KRW | 35.61% |
| 2018 Q3 | 42.18 Billion KRW | 8.16% |
| 2017 Q4 | 50.29 Billion KRW | 0.2% |
| 2017 Q2 | 45.97 Billion KRW | -5.28% |
| 2017 Q1 | 48.54 Billion KRW | -5.92% |
| 2017 Q3 | 50.19 Billion KRW | 9.16% |
| 2017 FY | 195 Billion KRW | 0.97% |
| 2016 Q3 | 50.49 Billion KRW | 12.57% |
| 2016 Q4 | 51.59 Billion KRW | 2.19% |
| 2016 FY | 193.13 Billion KRW | 13.47% |
| 2016 Q1 | 46.18 Billion KRW | -1.09% |
| 2016 Q2 | 44.85 Billion KRW | -2.89% |
| 2015 Q2 | 42.67 Billion KRW | 13.75% |
| 2015 Q4 | 46.69 Billion KRW | 7.83% |
| 2015 Q3 | 43.3 Billion KRW | 1.47% |
| 2015 FY | 170.2 Billion KRW | 1.57% |
| 2015 Q1 | 37.52 Billion KRW | -18.28% |
| 2014 Q4 | 45.91 Billion KRW | 8.52% |
| 2014 Q3 | 42.31 Billion KRW | 7.83% |
| 2014 Q2 | 39.23 Billion KRW | -2.17% |
| 2014 Q1 | 40.1 Billion KRW | 7.39% |
| 2014 FY | 167.56 Billion KRW | 6.99% |
| 2013 FY | 156.62 Billion KRW | 13.75% |
| 2013 Q3 | 38.97 Billion KRW | -8.66% |
| 2013 Q2 | 42.67 Billion KRW | 13.43% |
| 2013 Q1 | 37.62 Billion KRW | -4.79% |
| 2013 Q4 | 37.34 Billion KRW | -4.18% |
| 2012 FY | 137.68 Billion KRW | 22.82% |
| 2012 Q4 | 39.51 Billion KRW | 6.11% |
| 2012 Q3 | 37.23 Billion KRW | 9.78% |
| 2012 Q2 | 33.92 Billion KRW | 25.58% |
| 2012 Q1 | 27.01 Billion KRW | -11.57% |
| 2011 Q3 | 24.83 Billion KRW | -6.89% |
| 2011 Q1 | 30.05 Billion KRW | 7.52% |
| 2011 Q4 | 30.54 Billion KRW | 23.0% |
| 2011 Q2 | 26.67 Billion KRW | -11.25% |
| 2011 FY | 112.1 Billion KRW | -3.62% |
| 2010 Q2 | 30.27 Billion KRW | -0.84% |
| 2010 Q1 | 30.52 Billion KRW | 11.56% |
| 2010 Q4 | 27.95 Billion KRW | 1.39% |
| 2010 Q3 | 27.56 Billion KRW | -8.92% |
| 2010 FY | 116.31 Billion KRW | 12.52% |
| 2009 FY | 103.37 Billion KRW | -6.75% |
| 2009 Q4 | 27.36 Billion KRW | 7.37% |
| 2009 Q3 | 25.48 Billion KRW | -6.62% |
| 2009 Q2 | 27.29 Billion KRW | 17.44% |
| 2009 Q1 | 23.23 Billion KRW | -24.7% |
| 2008 Q3 | 25.54 Billion KRW | -8.03% |
| 2008 Q4 | 30.86 Billion KRW | 20.81% |
| 2008 Q2 | 27.77 Billion KRW | 4.09% |
| 2008 FY | 110.86 Billion KRW | 1.1% |
| 2008 Q1 | 26.68 Billion KRW | 6.85% |
| 2007 Q2 | 27.38 Billion KRW | -10.31% |
| 2007 Q3 | 27.14 Billion KRW | -0.89% |
| 2007 Q1 | 30.53 Billion KRW | 0.0% |
| 2007 Q4 | 24.97 Billion KRW | -8.0% |
| 2007 FY | 109.65 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -71.2% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 79.249% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 63.207% |
| HANDOK Inc. | 522.74 Billion KRW | 55.063% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -73.523% |
| Yuhan Corporation | 1858.98 Billion KRW | 87.364% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 64.622% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -352.126% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 84.244% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -74.118% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 36.605% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -165.146% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -38.53% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -4.654% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -71.2% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -200.952% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -55.491% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -168.879% |
| JW Holdings Corporation | 928.07 Billion KRW | 74.689% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 60.899% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 85.929% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 68.618% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -17.317% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -29.951% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -19.637% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 67.662% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -71.2% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 84.489% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 82.92% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 68.618% |
| Yuhan Corporation | 1858.98 Billion KRW | 87.364% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 70.442% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 60.492% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 68.618% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 19.589% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 15.788% |
| CKD Bio Corp. | 160.35 Billion KRW | -46.491% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 55.422% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 34.95% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -1.957% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -17.317% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 73.3% |
| Boryung Corporation | 859.62 Billion KRW | 72.674% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -86.537% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 36.605% |
| JW Lifescience Corporation | 206.86 Billion KRW | -13.556% |